A Study of CS1002 in Subjects With Advanced Solid Tumors
A Phase Ia/Ib, Open-Label, Dose-Escalation, and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 as Monotherapy and in Combination With Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New South Wales
-
Albury, New South Wales, Australia, 2640
- Border Medical Oncology Research Unit
-
Orange, New South Wales, Australia, 2800
- Orange Health Service
-
Sydney, New South Wales, Australia, 2010
- St Vincent's Hospital
-
Wollongong, New South Wales, Australia, 2500
- Southern Medical Day Care Centre
-
-
South Australia
-
Adelaide, South Australia, Australia, 5037
- Ashford Cancer Centre Research
-
-
Victoria
-
Malvern, Victoria, Australia, 3186
- Cabrini Health
-
Melbourne, Victoria, Australia, 3004
- Alfred Hospital
-
Melbourne, Victoria, Australia, 3128
- Boxhill Hospital
-
-
-
-
-
Hong Kong, Hong Kong
- Queen Mary Hospital
-
Hong Kong, Hong Kong
- Prince of Wales Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with histologically or cytologically confirmed advanced or metastatic solid tumor(s) for which no effective standard therapy is available or tolerable.
- ECOG performance status of 0 or 1.
- Life expectancy ≥12 weeks.
- Subjects must have adequate organ function
- Use of effective contraception
Exclusion Criteria:
- Known brain metastasis or other CNS metastasis that is either symptomatic or untreated.
- Subjects with active autoimmune diseases or history of autoimmune diseases.
- Subjects with immunodeficiency or receiving systemic steroid therapy or any other immunosuppressive therapy within 14 days prior to the first dose of CS1002.
- Has received prior therapy with an anti-CTLA-4 agent.
- Subjects who had prior chemotherapy, targeted therapy, immunotherapy or any other anti cancer systemic treatment, within 14 days prior to the first dose of CS1002 or who has not recovered from adverse events due to prior therapy.
- Receipt of major surgical procedure, wide field of radiation, local radiotherapy or radioactive agents within specified time frame prior to the first dose of CS1002.
- Receipt of live vaccine within 28 days prior to the first dose of CS1002
- Use of traditional medicinal herbal preparations within 7 days prior to the first dose of CS1002.
- History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies.
- Known history of HIV.
- Subjects with active Hepatitis B or C infection
- Subjects with active tuberculosis infection.
- Subjects with an active infection requiring systemic therapy.
- History of organ transplantation.
- History of alcoholism or drugs abuse.
- History of severe hypersensitivity reactions to other mAbs.
- Subjects with major cardiovascular diseases.
For more information regarding trial participation, please contact at cstonera@cstonepharma.com
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: CS1002
Participants will receive CS1002 intravenously at specified dose on specified days.
|
Dose levels will be escalated following a modified 3+3 dose escalation scheme
Other Names:
Fixed dose at 200mg in combination with CS1002 on a specified dose level
Other Names:
|
|
EXPERIMENTAL: CS1003
Participants will receive CS1003 intravenously at fixed dose on specified days.
|
Dose levels will be escalated following a modified 3+3 dose escalation scheme
Other Names:
Fixed dose at 200mg in combination with CS1002 on a specified dose level
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of participants with adverse events
Time Frame: From the day of first dose to 30 days after last dose of CS1002
|
From the day of first dose to 30 days after last dose of CS1002
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Wanmei Wang, CStone Pharmaceuticals
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CS1002-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.